Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Prenuvo has opened an imaging biobank of more than 200,000 whole-body MRI scans to over 50 research institutions, accompanied by four initial studies. The largest reported that roughly 7% of 78,000 self-referred individuals had a clinically significant brain abnormality, including aneurysms, infarcts and meningiomas. The data come from a self-selected population, and whether detection of such findings translates into longer healthy life remains unresolved.
United Therapeutics will report phase 3 and registry data at CHEST 2026 indicating that ralinepag reduced clinical worsening risk in pulmonary arterial hypertension irrespective of baseline noninvasive risk status, and that nebulized treprostinil lowered disease progression events in idiopathic pulmonary fibrosis. Interim data from the PHINDER and DeciPHer-ILD studies point to elevated mortality risk scores and advanced hemodynamic compromise in interstitial lung disease patients at the time of detection. Both agents remain investigational for these indications, with FDA applications under review.
In aged mice, influenza infection produced pronounced gut microbiota dysbiosis with depletion of short-chain fatty acid producers such as Akkermansia muciniphila and reduced microbial capacity for acetate production. In senescent human lung fibroblasts, acetate supplementation lowered viral replication and inflammatory signaling through FFAR2/FFAR3 receptors and increased histone H3 acetylation, identifying a metabolic and epigenetic route by which gut-derived metabolites support antiviral defense in aging tissue.
In a prespecified analysis of the DAN-RSV trial, RSV prefusion F vaccination lowered hospitalisations for RSV-related respiratory tract disease in adults aged 60 and older, with no statistical evidence that immunosuppression modified the effect. Because immunosuppressed participants carried a higher baseline risk of RSV hospitalisation, the absolute benefit of vaccination may be greatest in that group, though the analysis was not powered to rule out subgroup differences.
In a cohort of 861 adults followed from age 70 to 89, the GrimAge2 epigenetic clock was the single strongest correlate of all-cause mortality, while leukocyte telomere attrition showed no significant relationship. Four measures — white matter volume, total brain volume, walking time, and general cognitive function — carried the most independent predictive power, together explaining 19% of mortality variance, with 17 additional markers adding only 4%. GDF15, a protein linked to cellular senescence, ranked second only to GrimAge2 among individual markers.
VectorY Therapeutics has tripled enrollment in its Phase 1/2 PIONEER-ALS study of VTx-002, from 12 to 36 participants, before any efficacy readouts. The investigational agent is a vectorized antibody intended to produce sustained intrathecal antibody expression against pathological TDP-43, the protein the company reports aggregates abnormally in up to 97% of ALS patients. The expanded cohort is designed to strengthen the signal from secondary and exploratory endpoints, including neurofilament light chain and TDP-43 pathway biomarker trajectories.
In a 16-year follow-up of 861 older adults, epigenetic age (GrimAge2), brain and grey matter volume, respiratory function and cognitive performance predicted all-cause mortality more strongly than plasma proteomic organ clocks. Among 9703 protein targets, 368 were linked to mortality, with GDF15, WFDC2 and TIMP1 leading; elevated-risk proteins clustered in immune signalling while protective ones mapped to genomic stability and cellular maintenance.
In chronic obstructive pulmonary disease, elevated TNF-α drives p53-dependent upregulation of the mitochondrial enzyme Prodh2 in muscle progenitor cells, generating excess mitochondrial reactive oxygen species and leaking mitochondrial DNA into the cytosol, where it triggers the cGAS/STING innate immune sensor. The resulting apoptosis, proliferation arrest, and atrophy were reversed by muscle-specific Prodh2 knockdown, which restored strength in a mouse model. The work maps a specific molecular route by which chronic inflammation converts into measurable loss of muscle mass and function.
Prenuvo has established a research network built on an imaging biobank of more than 200,000 standardized whole-body MRI scans, offering controlled access to de-identified datasets and AI-generated statistical summaries. Four initial studies examine pulmonary and mediastinal findings, incidental brain abnormalities across more than 78,000 screened individuals, structural changes associated with alcohol intake in adults without alcohol use disorder, and renal findings across 117,826 scans. The scale shifts whole-body imaging from individual screening toward population-level characterization of subclinical disease.
A Phase Ib/IIa trial of Mabwell's anti-ST2 antibody 9MW1911 in 80 former smokers with moderate-to-severe COPD reported an 81% reduction in moderate-to-severe exacerbations and a 100% reduction in severe exacerbations at the 900mg dose, with a clean dose-response relationship. Because each exacerbation removes lung capacity that is not recovered, exacerbation control functions as a determinant of long-term functional reserve. Larger Phase IIb enrollment is complete and Phase III is anticipated around the end of 2026.
In a 90-day randomized, double-blind trial of 140 independently living adults aged 60 and older, supplementation with Polygonatum odoratum reduced terminally differentiated memory T cells (TEMRA, including the CD28−CD57+ senescent subset) while increasing Akkermansia and Prevotella 9 and lowering Klebsiella abundance. Baseline analysis showed gut microbial composition correlated most strongly with T cell subsets, and the intervention-associated microbial shifts tracked with improved immune profiles and fewer respiratory infections.
The FDA has accepted a supplemental application for nebulized Tyvaso, a prostacyclin analog delivered directly to the lungs, as the first inhaled antifibrotic therapy for idiopathic pulmonary fibrosis. Pooled phase 3 data from TETON-1 and TETON-2 showed a 111.8 mL improvement in forced vital capacity over placebo, alongside reduced risk of clinical worsening and acute exacerbation. Because fibrosis represents tissue that has lost its capacity to repair and instead scars, therapies that interrupt it bear directly on how quickly functional capacity declines with age.